Bicycle Therapeutics plc — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; the supplied filing text does not provide a separate fourth-quarter financial summary. Bicycle is a clinical-stage biopharmaceutical company developing synthetic bicyclic peptide medicines. It has no approved products and no product-sale revenue; collaboration income and external financing fund operations.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Collaboration revenue | $27.0 million | $14.5 million |
| Research and development expense | $156.5 million | $81.6 million |
| General and administrative expense | $60.4 million | $49.5 million |
| Total operating expenses | $216.9 million | $131.1 million |
| Operating loss | $189.9 million | $116.7 million |
| Net loss | $180.7 million | $112.7 million |
| Basic and diluted loss per share | $5.08 | $3.80 |
| Net cash used in operating activities | $60.6 million | $86.1 million |
- Net loss widened by $67.9 million year over year. R&D spending rose by $74.9 million, chiefly reflecting increased BT8009 and Bicycle TICA clinical activity, BT8009 registrational-trial startup, discovery investment, staffing and facilities. Collaboration revenue increased $12.5 million, including revenue from new Bayer and Novartis agreements and a $6.0 million Genentech material-right expiration.
- Cash and cash equivalents were $526.4 million at year-end, versus $339.2 million in 2022. Management said this was expected to fund operating expenses and capital expenditures for at least 12 months from the filing date; this estimate is subject to assumptions and may prove incorrect.
- Operating cash use fell despite the larger net loss, primarily because of $68.9 million in increased deferred revenue, including upfront collaboration payments. Investing cash use was $2.9 million. Financing provided $250.0 million, including $215.1 million net proceeds from a July public offering and $34.2 million net ATM proceeds.
- Outstanding Hercules borrowings were $30.0 million; the reported debt carrying value was $30.7 million. The loan rate was capped at 9.05%, with interest-only payments through April 1, 2025 and scheduled maturity in July 2025. Up to $45.0 million of additional borrowing was available, subject to conditions, through December 31, 2024.
- Year-end total assets were $595.3 million, total liabilities $224.4 million and shareholders’ equity $370.9 million. No product gross margin is reported because the company has no product sales.
Programs, developments and outlook
- BT8009: The Nectin-4 toxin conjugate was in Phase I/II testing, and its Phase II/III Duravelo-2 registrational trial was active and recruiting. The FDA granted Fast Track designation and aligned with the company on the registrational-trial design; BT8009 was also selected for the FDA’s CMC Development and Readiness Pilot Program. Company-reported interim data included a 38% objective response rate in 26 metastatic urothelial cancer patients receiving 5 mg/m² weekly who had not received enfortumab vedotin, with median response duration of 11.1 months in 10 patients. These are interim clinical results, not proof of approval or commercial success.
- BT5528: The EphA2 toxin conjugate remained in Phase I/II testing. Company-reported interim data showed a 39% objective response rate in 18 metastatic urothelial cancer patients treated across specified every-other-week doses; median response duration was four months in seven patients. Dose-optimization cohorts were underway, with data expected in the second half of 2024.
- BT7480: The Nectin-4/CD137 tumor-targeted immune agonist remained in Phase I dose escalation. Interim findings included two unconfirmed partial responses and prolonged stable disease in three patients; the company planned to define a Phase II dose and pursue combination cohorts in 2024.
- Other pipeline: BT7455 was in IND-enabling work. BT1718 was in a Cancer Research UK-sponsored Phase I/IIa trial. Bicycle was developing radionuclide conjugates and other discovery programs, and planned to select a next-generation BTC clinical candidate in the second half of 2024.
- Management expects expenses and losses to remain substantial as clinical and preclinical programs advance. The company anticipates needing additional funding over time; it has no committed external funding source and may use equity, debt, collaborations or licensing, potentially causing dilution, restrictive terms or surrender of rights.
Risks, contingencies and unusual items
- Clinical-stage risk is substantial: interim early-trial findings may not be replicated, candidates may fail safety or efficacy tests, trials may be delayed or enrollment may be difficult, and regulatory approval is uncertain. Bicycle molecules are a newer modality with limited regulatory precedent.
- The company relies on third parties for clinical research and manufacturing, has no commercial-scale manufacturing facilities, and faces supply, quality, capacity and cost risks. Competition includes established cancer therapies, including a marketed Nectin-4 antibody-drug conjugate.
- Cash needs, continued operating losses, potential dilution and Hercules covenants are material financial risks. Debt is secured by substantially all personal property and other assets, excluding intellectual property; default could increase interest and accelerate repayment.
- Potential future payments include up to $111.2 million under Cancer Research UK arrangements and $105.1 million under other agreements, contingent on milestones. The filing says their timing and likelihood could not be estimated. Contractual operating-lease payments totaled $15.8 million; reported debt obligations, including scheduled interest and final payments, totaled $35.3 million.
- The company recorded a $1.5 million income-tax provision in 2023, including a $2.4 million impact from a change in estimate regarding U.S. R&D cost capitalization. It also recorded a $0.3 million lease-termination loss after surrendering a U.K. lease.
- Genentech discontinued one collaboration program in June 2023; the company recognized $6.0 million as a material right expired. In January 2024, another Genentech program was discontinued, and the company expected to recognize approximately $10.4 million of revenue in Q1 2024, including $7.4 million from expiration of material rights; other Genentech programs remained ongoing.
- Oxurion’s THR-149 missed its Phase 2 primary endpoint. Oxurion announced and then reversed plans to file for bankruptcy in late 2023; Bicycle said it was evaluating its options under the collaboration. No material legal proceedings were reported. Management and the auditor reported effective internal control over financial reporting as of year-end.
Investor verification priorities
- Review the full clinical-trial datasets, patient counts, dose schedules, response-duration follow-up and adverse-event profiles for BT8009, BT5528 and BT7480; distinguish interim, company-reported results from registrational evidence.
- Track Duravelo-2 enrollment, trial design and endpoints, FDA interactions, and the timing and completeness of the company’s planned 2024 clinical updates.
- Assess the cash-burn trajectory and whether the stated runway remains adequate as trial costs rise; verify the assumptions behind management’s runway estimate and any future financing plans.
- Check Hercules repayment terms, available borrowing conditions, and the impact of equity issuance and share-based compensation on dilution.
- Monitor collaborator option exercise or expiry, Genentech program changes, future milestone prospects and the recognition of deferred collaboration revenue; collaboration revenue is not product sales.